Impact of preservatives' elimination on tolerance and efficacy of latanoprost
Autor: | R Kinasz, Wanda Romaniuk, Małgorzata Mulak, M Misiuk Hojlo, Jaromir Wasyluk, R Ortyl-Markiewicz, Anna Zaleska-Zmijewska, Joanna Wierzbowska, Karolina Podboraczyńska-Jodko, M Prost, Wojciech Lubiński, Marek Rękas, Maria Pomorska, L Mocko, Dariusz Rokicki |
---|---|
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Preservative genetic structures business.industry Glaucoma General Medicine medicine.disease eye diseases Ophthalmology Benzalkonium chloride chemistry.chemical_compound Tolerability Quality of life chemistry Anesthesia Medicine sense organs Latanoprost business Fluorescence staining medicine.drug |
Zdroj: | Acta Ophthalmologica. 92 |
ISSN: | 1755-375X |
DOI: | 10.1111/j.1755-3768.2014.t018.x |
Popis: | Purpose To compare the tolerance and efficacy of preservative-free latanoprost (latanoprost-PF) after switching from benzalkonium chloride containing agent (latanoprost-BAK). Methods 140 patients with glaucoma or OHT controlled by latanoprost–BAK were included into the study. At a baseline visit (D0) a new formulation of latanoprost-FP (Monoprost ®, Laboratoires Thea) was introduced. An observation was conducted, including three visits after 15, 45 and 90 days from the baseline (D15, D45, D90 respectively). The following outcomes were evaluated: BCVA, IOP, TBUT, corneal fluorescein staining and subjective assessment of tolerance by patient using 10- point VAS scale (0 - very good, 10 - very poor tolerance). Results Mean IOP during all subsequent visits was reduced compared to the baseline (p |
Databáze: | OpenAIRE |
Externí odkaz: |